Inovio Pharmaceuticals, Inc.
INO· Nasdaq
INOInovio Pharmaceuticals, Inc.
Filed Aug 8, 2024 · 10-Q · 39 days after period end · 0001055726-24-000046
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $100.76K | $225.97K | $784.40K | $272.82K |
| Net Income | -$32.24M | -$35.53M | -$108.50M | -$82.14M |
| EPS Diluted | -$1.19 | -$1.61 | -$0.46 | -$0.39 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 8, 2024 · 39 d after period end
